(Q37350190)

19 August 2017

1 reference

title

Neoadjuvant therapy for breast cancer: assessing treatment progress and managing poor responders (English)

1 reference

19 August 2017

Robert Wesolowski

1

1 reference

19 August 2017

Georg Thomas Budd

series ordinal

2

1 reference

19 August 2017

publication date

1 January 2009

1 reference

19 August 2017

published in

Current Oncology Reports

1 reference

19 August 2017

volume

11

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

37-44

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-009-0007-5

19 August 2017

exact match

0 references

cites work

Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-009-0007-5

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

21 January 2018

1 reference

12 December 2020

The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial

1 reference

12 December 2020

American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome

1 reference

12 December 2020

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

12 December 2020

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

12 December 2020

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

12 December 2020

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

12 December 2020

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

12 December 2020

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival

1 reference

12 December 2020

Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial

1 reference

12 December 2020

Letrozole in the neoadjuvant setting: the P024 trial

1 reference

12 December 2020

Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response

1 reference

12 December 2020

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

1 reference

12 December 2020

Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials

1 reference

12 December 2020

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

12 December 2020

Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI

1 reference

12 December 2020

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

12 December 2020

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

12 December 2020

Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score

1 reference

12 December 2020

Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study

1 reference

12 December 2020

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

1 reference

12 December 2020

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome

1 reference

12 December 2020

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease

1 reference

12 December 2020

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

12 December 2020

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial

1 reference

12 December 2020

MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer

1 reference

12 December 2020

Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference

1 reference

12 December 2020

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

12 December 2020

Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status

1 reference

12 December 2020

Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy

1 reference

12 December 2020

10.1007/S11912-009-0007-5

Identifiers

DOI

1 reference

19 August 2017

1 reference